Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 17/20 | 0.48 |
| ▸ | F11 | P03951 | 6/20 | 0.34 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23241532 | 1.00 | CFD (0.48) | CFDF11TPSB2SYKKLKB1 | |
| SCHEMBL23217548 | 0.91 | CFD (0.58) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23217547 | 0.91 | CFD (0.58) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23241531 | 0.90 | CFD (0.53) | CFDF11TPSB2SYKKLKB1 | |
| SCHEMBL28772685 | 0.90 | CFD (0.53) | CFDF11TPSB2SYKKLKB1 | |
| SCHEMBL28772753 | 0.88 | CFD (0.47) | CFDF11TPSB2SYKTBXAS1 | |
| SCHEMBL23217644 | 0.86 | CFD (0.55) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL30010496 | 0.86 | CFD (0.55) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23217693 | 0.84 | CFD (0.43) | CFDSYKTBXAS1 | |
| SCHEMBL23217690 | 0.84 | CFD (0.43) | CFDSYKTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CFD 1/4885F11 15/4885TPSB2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.